New Enterprise Associates
New Enterprise Associates, Inc. (NEA) is a leading venture capital firm focused on helping entrepreneurs create and build major new enterprises that use technology to improve the way we live, work and play. Since its founding in 1978, the firm has followed the same core principles: supporting its entrepreneurs, providing an excellent return to its limited partners, and practicing its profession with the highest standards and respect. Through its affiliated funds, NEA focuses on investments at all stages of a company’s development, from seed stage through IPO. With approximately $8.5 billion in committed capital, NEA’s experienced management team has invested in over 650 companies, of which more than 160 have gone public and more than 250 have been acquired. NEA has U.S. offices in Chevy Chase, Maryland; Menlo Park, California; and Baltimore, Maryland. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China.
www.nea.com

Canaan Partners
Canaan Partners invests in visionary entrepreneurs and provides them the networks, insights and operational guidance required to build high-performance technology and healthcare companies. Founded in 1987, the firm has raised eight funds and completed more than 78 acquisitions and 53 IPOs. With $3 billion under management and a worldwide footprint, the firm is committed to catalyzing the growth of innovative digital media, communications & mobility, enterprise, clean tech, biopharmaceutical, medical device, diagnostics and healthcare infrastructure companies. Among its successes are Amicus Therapeutics, a pioneer of next-generation oral therapies for the management of human genetic diseases; BiPar Sciences, a biopharmaceutical company pioneering novel tumor-selective therapies to address urgent unmet needs of cancer patients; Calixa Therapeutics, developer of hospital-based antibiotics to treat infections resulting from resistant strains of bacteria; and Cerexa Inc., one of the largest biotech acquisitions of 2007. Other Canaan investments include Advanced BioHealing, Calibra Medical, Chimerix, Inc., CoAxia, Liquidia Technologies, ReVision Optics, Theraclone Sciences, Transcend Medical, and VaxInnate. Canaan has offices in California, Connecticut, India and Israel.
www.canaan.com

Firelake Capital Management
Firelake Capital is a "hybrid" investment fund, driven by research in three areas where technology can significantly disrupt the economics of the current market - information technology, energy technology, and material science. Portfolio companies include public and private investments across the entire value chain of various markets. Firelake is headquartered in Palo Alto, CA.
www.firelakecapital.com

Pappas Ventures
Founded in 1994, Pappas Ventures has more than $350 million in capital under management. Pappas Ventures has guided the launch and/or development of some 40 life sciences companies, a quarter of which have completed initial public offerings or successfully merged with corporate partners. Scientific, medical and business professionals on the Pappas team work closely with exceptional entrepreneurs to provide portfolio companies with the financing, guidance and extensive network of relationships necessary to build successful enterprises. Pappas Ventures is based in Research Triangle Park, NC.
www.pappasventures.com

Wakefield Group
Wakefield Group is a venture capital firm focused on providing growth capital to growing businesses. The firm focuses its investments in technology, health, and business services and media. Within healthcare the firm focuses on software, devices, and human-genome technologies. Wakefield Group was founded in 1988 and has offices in Charlotte and Chapel Hill, North Carolina.

Other investors include Siemens Venture Capital and private investors.